<DOC>
	<DOCNO>NCT00090870</DOCNO>
	<brief_summary>RATIONALE : PEG-interferon alfa-2b may interfere growth tumor cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood . Thalidomide may stop growth cancer stop blood flow tumor . Combining PEG-interferon alfa-2b sargramostim thalidomide may kill tumor cell . PURPOSE : This phase II trial study well give PEG-interferon alfa-2b together sargramostim thalidomide work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>PEG-Interferon Alfa-2b , Sargramostim , Thalidomide Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response PEG-interferon alfa-2b , sargramostim ( GM-CSF ) , thalidomide patient metastatic renal cell carcinoma . Secondary - Determine duration response patient treat regimen . - Determine tolerance toxicity regimen patient . - Determine median progression-free survival patient treat regimen . OUTLINE : Patients receive PEG-interferon alfa-2b subcutaneously ( SC ) day 1 8 , sargramostim ( GM-CSF ) SC day 1-10 , oral thalidomide daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Metastatic disease Measurable disease Unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan MRI Histologic confirmation require measurable disease confine solitary lesion The following consider measurable disease : Bone disease Pleural peritoneal metastasis CNS lesion Irradiated lesion unless disease progression document prior radiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL No decompensated liver disease Renal Creatinine ≤ 2.0 mg/dL Immunologic No known suspect hypersensitivity interferon alfa excipient vehicle include formulation delivery system No history autoimmune disease No autoimmune hepatitis No immunosuppressed transplantation recipient Other Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective method contraception 4 week , , 4 week study participation No preexisting thyroid abnormality thyroid function maintain normal range No severe psychiatric condition disorder , include suicidal ideation attempt No active malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>